Last reviewed · How we verify
GSK Bio's influenza vaccine GSK2186877A
GSK Bio's influenza vaccine GSK2186877A is a Recombinant influenza vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Influenza prevention (seasonal influenza).
GSK2186877A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus through a novel antigenic approach.
GSK2186877A is a recombinant influenza vaccine designed to stimulate immune responses against influenza virus through a novel antigenic approach. Used for Influenza prevention (seasonal influenza).
At a glance
| Generic name | GSK Bio's influenza vaccine GSK2186877A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine candidate uses recombinant technology to present influenza antigens in a way intended to broaden and enhance immune recognition across multiple influenza strains. The specific mechanism leverages GSK's vaccine platform technology to improve upon traditional seasonal influenza vaccines by potentially offering improved immunogenicity or broader strain coverage.
Approved indications
- Influenza prevention (seasonal influenza)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Systemic reactions (fever, myalgia, fatigue)
- Headache
Key clinical trials
- Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly (PHASE3)
- Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older (PHASE3)
- Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Bio's influenza vaccine GSK2186877A CI brief — competitive landscape report
- GSK Bio's influenza vaccine GSK2186877A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Bio's influenza vaccine GSK2186877A
What is GSK Bio's influenza vaccine GSK2186877A?
How does GSK Bio's influenza vaccine GSK2186877A work?
What is GSK Bio's influenza vaccine GSK2186877A used for?
Who makes GSK Bio's influenza vaccine GSK2186877A?
What drug class is GSK Bio's influenza vaccine GSK2186877A in?
What development phase is GSK Bio's influenza vaccine GSK2186877A in?
What are the side effects of GSK Bio's influenza vaccine GSK2186877A?
Related
- Drug class: All Recombinant influenza vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Influenza prevention (seasonal influenza)
- Compare: GSK Bio's influenza vaccine GSK2186877A vs similar drugs
- Pricing: GSK Bio's influenza vaccine GSK2186877A cost, discount & access